Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02864251
Title A Study of Nivolumab + Chemotherapy or Nivolumab + Ipilimumab Versus Chemotherapy in NSCLC Patients With EGFR Mutation Who Failed 1L or 2L EGFR TKI Therapy (CheckMate722)
Recruitment Active, not recruiting
Gender both
Phase Phase III
Variant Requirements Yes
Sponsors Bristol-Myers Squibb
Indications

lung non-small cell carcinoma

Therapies

Carboplatin + Nivolumab + Pemetrexed Disodium

Cisplatin + Pemetrexed Disodium

Cisplatin + Nivolumab + Pemetrexed Disodium

Ipilimumab + Nivolumab

Carboplatin + Pemetrexed Disodium

Age Groups: senior | adult
Covered Countries USA | FRA | ESP

Additional content available in CKB BOOST